Healthcare Industry News: neurodegenerative
News Release - August 30, 2013
EMD Serono President and Head of US Operations James Hoyes ResignsROCKLAND, Mass.--(Healthcare Sales & Marketing Network)--EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that James Hoyes has resigned from his position as President and Head of US Operations. Following nearly a decade of dedicated service to EMD Serono, Hoyes has decided to pursue other professional opportunities. His last day with the organization will be Sept 30, 2013.
Hoyes joined EMD Serono in 2004 as Vice President of Marketing in neurology and since that time has held positions of increasing responsibility, including leading the neurology franchise. Prior to being named President and Head of US Operations in 2011, Hoyes served as Chief Commercial Officer for EMD Serono, where he was responsible for business operations in the company’s key therapeutic areas of neurodegenerative diseases, fertility and metabolic endocrinology, as well as managed care, business intelligence, health outcomes, specialty pharmacy and commercial operations.
“We would like to thank Jim for his leadership and contributions to the company over the last decade,” said Belén Garijo, Executive Vice President, Chief Operating Officer for Merck Serono. “Jim has been highly committed to this organization and a key driver of our US brands. His work has been instrumental in positioning the company for continued growth in the future.”
The US is a key growth market for Merck KGaA, and a search is underway to fill this important role in the organization. “This is an opportunity for the company to seek out the leadership and fresh perspectives of an individual who will help lead our US business to further growth,” said Garijo.
About EMD Serono, Inc.
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to improve people's lives. The company has strong market positions in neurodegenerative diseases, endocrinology and in reproductive health. In addition, EMD Serono is growing its expertise and presence in the area of oncology, with more than 15 projects currently in development. With a clear focus on the patient and a leadership presence in the biopharmaceutical industry, EMD Serono’s US footprint continues to grow, with approximately 1,000 employees around the country and fully integrated commercial, clinical and research operations in the company’s home state of Massachusetts.
For more information, please visit www.emdserono.com
About Merck KGaA
Merck is a leading pharmaceutical, chemical and life science company with total revenues of € 11.2 billion in 2012, a history that began in 1668, and a future shaped by approx. 38,000 employees in 66 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
Source: EMD Serono
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.